HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Claude Leclerc Selected Research

Tn antigen

5/2020The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients.
12/2016Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate.
3/2016The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.
10/2015The Quest for Anticancer Vaccines: Deciphering the Fine-Epitope Specificity of Cancer-Related Monoclonal Antibodies by Combining Microarray Screening and Saturation Transfer Difference NMR.
6/2013Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer.
3/2011Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses.
7/2004A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates.
7/2004Synthesis and immunological evaluation of an antitumor neoglycopeptide vaccine bearing a novel homoserine Tn antigen.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Claude Leclerc Research Topics

Disease

31Neoplasms (Cancer)
12/2020 - 06/2002
13Infections
11/2015 - 01/2002
10Tuberculosis (Tuberculoses)
01/2016 - 07/2004
6Inflammation (Inflammations)
01/2016 - 03/2005
5Breast Neoplasms (Breast Cancer)
05/2020 - 05/2006
5Carcinoma (Carcinomatosis)
01/2018 - 07/2004
5Communicable Diseases (Infectious Diseases)
08/2014 - 03/2002
5Acquired Immunodeficiency Syndrome (AIDS)
10/2010 - 10/2003
3Psychotic Disorders (Schizoaffective Disorder)
06/2015 - 03/2013
3Melanoma (Melanoma, Malignant)
08/2014 - 06/2002
3Malaria
04/2007 - 10/2003
2Adenocarcinoma
05/2020 - 03/2011
2Bites and Stings (Sting)
01/2019 - 08/2014
2Disease Progression
01/2017 - 01/2016
2Whooping Cough (Pertussis)
01/2012 - 10/2003
2Persistent Infection
07/2008 - 02/2004
2Bovine Spongiform Encephalopathy (Mad Cow Disease)
06/2008 - 05/2006
1Autoimmune Diseases (Autoimmune Disease)
11/2018
1Uterine Cervical Neoplasms (Cancer of the Cervix)
08/2015
1Mental Disorders (Mental Disorder)
04/2014
1Colonic Neoplasms (Colon Cancer)
06/2013
1Prion Diseases (Transmissible Spongiform Encephalopathies)
06/2008
1HIV Infections (HIV Infection)
07/2007
1Pulmonary Tuberculosis
07/2007

Drug/Important Bio-Agent (IBA)

27VaccinesIBA
12/2020 - 03/2002
23AntigensIBA
05/2020 - 07/2004
12Proteins (Proteins, Gene)FDA Link
08/2012 - 01/2002
10EpitopesIBA
11/2018 - 06/2002
8Tn antigenIBA
05/2020 - 07/2004
6CarbohydratesIBA
05/2020 - 07/2004
5AntibodiesIBA
05/2020 - 07/2004
5Peptides (Polypeptides)IBA
03/2016 - 02/2002
4GlycopeptidesIBA
05/2020 - 07/2004
4Interleukin-10 (Interleukin 10)IBA
01/2016 - 04/2005
4Adenylyl Cyclases (Adenylyl Cyclase)IBA
09/2007 - 11/2004
3T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
12/2016 - 11/2006
3Monoclonal AntibodiesIBA
10/2015 - 05/2006
3Recombinant ProteinsIBA
04/2012 - 01/2005
2Therapeutic UsesIBA
12/2020 - 01/2018
2InterferonsIBA
01/2019 - 05/2007
2CytokinesIBA
01/2018 - 03/2005
2ChemokinesIBA
01/2018 - 03/2005
2Influenza Vaccines (Influenza Vaccine)FDA Link
01/2017 - 01/2016
2Cancer VaccinesIBA
01/2016 - 06/2013
2Membrane Proteins (Integral Membrane Proteins)IBA
09/2014 - 06/2002
2LipidsIBA
08/2012 - 09/2007
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/2012 - 09/2007
2Poly I-CIBA
08/2012 - 10/2010
2Neoplasm Antigens (Tumor Antigens)IBA
03/2011 - 10/2010
2MucinsIBA
03/2011 - 05/2006
2Prion ProteinsIBA
06/2008 - 05/2006
2Tuberculin (PPD)IBA
07/2007 - 05/2005
2GlycoconjugatesIBA
05/2006 - 07/2004
2Interleukin-12 (IL 12)IBA
04/2005 - 02/2002
2Adenylate Cyclase ToxinIBA
12/2003 - 10/2003
1Interleukin-17 (Interleukin 17)IBA
12/2020
1Complement System Proteins (Complement)IBA
05/2020
1IntegrasesIBA
01/2019
1Tretinoin (Retinoic Acid)FDA LinkGeneric
01/2019
1Interferon Regulatory FactorsIBA
01/2019
1OVA 323-339IBA
11/2018
1Toll-Like Receptor 7IBA
11/2018
1Peptide TIBA
11/2018
1Histocompatibility Antigens Class IIIBA
01/2018
1Tetanus Toxoid (Vaccine, Tetanus)FDA Link
03/2016
1Immunologic Adjuvants (Immunologic Adjuvant)IBA
03/2016
1Synthetic Vaccines (Recombinant Vaccines)IBA
03/2016
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2016
1Sirolimus (Rapamycin)FDA Link
08/2015
1Protein Subunit VaccinesIBA
08/2015
1chenodeoxycholate sulfate conjugate (CDCS)IBA
08/2014
1Amino AcidsFDA Link
06/2013
1Antiviral Agents (Antivirals)IBA
01/2013
1Fibronectins (Fibronectin)IBA
08/2012
1LigandsIBA
08/2012
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
07/2012
11,2- dioleoyloxy- 3- (trimethylammonium)propaneIBA
07/2012
1Viral VaccinesIBA
04/2012
1AnaphylatoxinsIBA
04/2012
1CalciumIBA
01/2012
1LectinsIBA
11/2010
1Galactose (Galactopyranose)FDA LinkGeneric
11/2010
1Peptide Hydrolases (Proteases)FDA Link
06/2008
1flt3 ligand protein (flt3 ligand)IBA
06/2008
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
06/2008
1OligodeoxyribonucleotidesIBA
06/2008
1Mycobacterium tuberculosis antigensIBA
07/2007
1Interferon-gamma (Interferon, gamma)IBA
07/2007
1alpha-Crystallins (alpha-Crystallin)IBA
07/2007
1InterleukinsIBA
05/2007
1Interferon Type IIBA
05/2007
1Cell ExtractsIBA
05/2006
1Glycoproteins (Glycoprotein)IBA
05/2006
1LipopolysaccharidesIBA
05/2006
1Subunit VaccinesIBA
04/2006

Therapy/Procedure

6Immunotherapy
07/2012 - 06/2002
5Therapeutics
03/2016 - 10/2010
1Cognitive Training
04/2014
1Intravenous Injections
08/2012
1Cell- and Tissue-Based Therapy (Cell Therapy)
09/2008